UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000038014
Receipt number R000042407
Scientific Title The effects of ubiquinol supplementation on maintaining of cognitive performance and the changes in oral bacterial flora: randomized, double-blind, placebo-controlled trial
Date of disclosure of the study information 2019/09/17
Last modified on 2021/02/16 23:51:14

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Anti-aging from Wakamiya erea! Wakawaka noukatsu! The strategy for prolonging healthy life expectancy

Acronym

Wakawaka Noukatsu!

Scientific Title

The effects of ubiquinol supplementation on maintaining of cognitive performance and the changes in oral bacterial flora: randomized, double-blind, placebo-controlled trial

Scientific Title:Acronym

Ubiquinol and cognitive performance: RCT

Region

Japan


Condition

Condition

Healthy adult

Classification by specialty

Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To investigate the effect of ubiquinol supplementation on maintaining cognitive performance

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

cognitive performance

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Double blind -all involved are blinded

Control

Placebo

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Prevention

Type of intervention

Food

Interventions/Control_1

Intake of 100 mg ubiquinol after breakfast everyday for 24 weeks.

Interventions/Control_2

Intake of 100 mg placebo capsule after breakfast everyday for 24 weeks.

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

50 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

(1) Those who can participate in the health examination
(2) Those whose age at the time of random allocation is 50 and over
(3) Those who can understand the purpose and the contents of this study, and can agree with participation by letter

Key exclusion criteria

(1) The presence of allergic response to test foods.
(2) Pregnancy or beast-feeding.
(3) Those who participated in other clinical trials within three months of agreement.
(4) Those who consume coenzyme Q10 supplements routinely.
(5) Possibly dementia
(6) Those who have past medical history of celebrovascular disease such as stroke
(7) In addition, those who were judged inadequate by the principal investigator.

Target sample size

110


Research contact person

Name of lead principal investigator

1st name Tetsu
Middle name
Last name Kinoshita

Organization

Institute of Community Life Sciences Co., Ltd.

Division name

Social Epidemiology Institute

Zip code

791-0243

Address

1383-2 Hiraimachi, Matsuyama-city, Ehime

TEL

0899047811

Email

tetsu.prospective@gmail.com


Public contact

Name of contact person

1st name Tetsu
Middle name
Last name Kinoshita

Organization

Institute of Community Life Sciences Co., Ltd.

Division name

Social Epidemiology Institute

Zip code

791-0243

Address

1383-2 Hiraimachi, Matsuyama-city, Ehime

TEL

0899047811

Homepage URL


Email

tetsu.prospective@gmail.com


Sponsor or person

Institute

Institute of Community Life Sciences Co., LtD.

Institute

Department

Personal name



Funding Source

Organization

Kaneka Corporation

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Institutional Review Board (IRB) of Ehime University Hospital

Address

Shitukawa, Toon, Ehime

Tel

089-960-5172

Email

rinri@m.ehime-u.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2019 Year 09 Month 17 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled

91

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2019 Year 08 Month 26 Day

Date of IRB

2019 Year 08 Month 26 Day

Anticipated trial start date

2019 Year 09 Month 21 Day

Last follow-up date

2020 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2019 Year 09 Month 14 Day

Last modified on

2021 Year 02 Month 16 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000042407


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name